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Abstract (200 words) 42 
Background While the association between renal impairment and cardiovascular disease (CVD) is well 43 
established in the general population, the association remains poorly understood in HIV-positive 44 
individuals.  45 
Methods Individuals with >2 estimated glomerular filtration rate (eGFRs) after 1/2/2004 were followed 46 
until CVD, death, last visit plus six months or 1/2/2015. CVD was defined as centrally validated myocardial 47 
infarction, stroke, invasive cardiovascular procedures or sudden cardiac death.  48 
Results During 8.0 years median follow-up (Interquartile range 5.4-8.9) 1,357 of 35,357 developed CVD 49 
(incidence 5.2/1000 person-years [95%confidence interval, CI [5.0-5.5]). Confirmed baseline eGFR and CVD 50 
were closely related with 1.8% [95%CI 1.6-2.0%] estimated to develop CVD at five years at eGFR>90 51 
ml/min/1.73m2, increasing to 21.1% [95%CI 6.6-35.6%] at eGFR<30 ml/min/1.73m2. The strong univariate 52 
relationship between low current eGFR and CVD was primarily explained by increasing age in adjusted 53 
analyses, although all eGFRs<80 ml/min/1.73m2 remained associated with 30-40% increased CVD rates and 54 
particular high rates at eGFR<30 ml/min/1.73m2 (3.08 [95%CI 2.04-4.65]). 55 
Conclusions Among HIV-positive individuals in a large contemporary cohort a strong relation between 56 
confirmed impaired eGFR and CVD was observed. This finding highlights the need for renal preventive 57 
measures and intensified monitoring for emerging CVD, in particular in older individuals with continuously 58 
low eGFR. 59 
 60 
Keywords: eGFR, renal impairment, kidney disease, cardiovascular disease, myocardial infarction, stroke, 61 
invasive cardiovascular procedures, sudden cardiac death, HIV 62 
 63 
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Text (3456 words) 64 
Introduction  65 
The association between impaired renal function and cardiovascular disease (CVD) is well established in the 66 
general population, in particular for severe levels of renal impairment [1-6]. As such more than 50% of all 67 
deaths in individuals with end-stage renal disease are related to a CVD event [7]. In contrast, most prior 68 
studies that have investigated the relation between renal impairment and CVD in HIV-positive individuals 69 
have been small, have used relatively broad definitions of CVD, or have focused on single measures of renal 70 
function which are subjected to random variation and the transient effects of acute illness [8-13]. The 71 
influence of a more sustained impairment of estimated glomerular filtration rate (eGFR) on well-defined 72 
CVD events in HIV-positive individuals is less clear. 73 
Renal impairment is projected to become more prevalent among HIV-positive individuals in future years 74 
due to ageing and an accumulating burden of comorbidities and lifestyle related risk factors.                                                                                                                                                                                                                                                                                                              75 
CVD is furthermore now one of the leading causes of non-AIDS death in HIV-positive individuals [14]. A 76 
better understanding of the rates of CVD among HIV-positives individuals with renal impairment is 77 
therefore warranted to assist identification of those at highest risk with a need for intensified monitoring 78 
and initiation of preventive measures [15] 79 
The relationship between renal impairment and CVD is complex and may be mediated through a variety of 80 
different pathways [3, 6, 14]. These include accelerated coronary- and cerebrovascular atherosclerosis 81 
which may be mediated in part by increased inflammation and oxidative stress, atrial fibrillation and 82 
ventricular hypertrophy, which are common at severe levels of renal impairment and may, similar to 83 
electrolyte abnormalities, promote dysrhythmias resulting in stroke or sudden cardiac death [3, 15-20]. 84 
Finally renal impairment and CVD are known to share a common underlying risk factor profile which include 85 
hypertension, diabetes, dyslipidemia, smoking, injecting drug use, obesity, on-going inflammation and black 86 
African origin [20, 21]. CVD, renal impairment, and many of the underlying shared individual risk factors, 87 
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are more prevalent among HIV-positive individuals than in the general population, hence the association 88 
between renal impairment and CVD may be stronger in HIV-positive individuals [22, 23]. The aim of this 89 
analysis is to investigate the nature and relationship of various levels of sustained eGFR impairment with 90 
centrally adjudicated CVD endpoints in a large heterogeneous and contemporary cohort of primarily 91 
Caucasian HIV-positive individuals.  92 
Methods 93 
Study population 94 
The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study  is a large, prospective cohort 95 
collaboration established in 1999 following more than 49,000 HIV-1-positive persons from 11 cohorts in 96 
Europe, the United States and Australia; details have been published previously [17]. Data on centrally 97 
validated clinical events including myocardial infarction, sudden cardiac death, stroke, invasive 98 
cardiovascular procedures, end-stage renal disease and fatal cases is collected in real-time during routine 99 
clinical care. Information on socio-demographic factors, antiretroviral treatment, HIV viral load, CD4 counts, 100 
AIDS events, viral hepatitis, creatinine and other laboratory biomarkers and cardiovascular risk factors is 101 
collected electronically at enrolment and every six months.  102 
Endpoint definition 103 
CVD events are reported using designated event forms (more information at 104 
www.chip.dk/Studies/DAD/Study-Documents) and are defined as centrally validated fatal and non-fatal 105 
myocardial infarction, stroke, coronary angioplasty, coronary bypass, carotid endarterectomy and sudden 106 
cardiac death. A fatal CVD event is defined as one of the above events leading to death within 28 days. 107 
Adjudication of CVD events is made in accordance with predefined algorithms, and only confirmed events 108 
are included in analysis. Sudden cardiac death is defined as a sudden death event in which the underlying 109 
cause of death could not be established as a myocardial infarction due to the lack of data on symptoms,  110 
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electrocardiogram  findings and changes in cardiac biomarker, but with cardiovascular risks  present at time of 111 
death according to the WHO MONICA Dundee score [24], and no evidence of other non-atherosclerotic or non-112 
cardiovascular causes of death. All sudden cardiac deaths in the D:A:D study are reviewed by an external 113 
cardiologist.  114 
Statistical methods 115 
D:A:D Study participants with >2 eGFR measurements after 1/2/2004 (baseline for initiation of systematic 116 
creatinine collection) were included and followed until the earliest of first CVD event, death, six months 117 
after last visit or 1/2/2015. Persons with less than three months follow-up from the first to last eGFR were 118 
excluded. The Cockcroft-Gault equation [25], standardized for body surface area [26], was used to estimate 119 
creatinine clearance, a surrogate for eGFR in this analysis [27, 28]. As several cohorts participating in D:A:D 120 
are prohibited from collecting ethnicity information, the Cockcroft-Gault equation was used rather than an 121 
equation including ethnicity. Where eGFR measurements were carried out more frequently than every 28 122 
days, the median value was used and assigned to the median date. Confirmed baseline and time-updated 123 
(current) eGFR levels were defined using two consecutive eGFR measurements, regardless of time between 124 
measurements (per definition minimum 28 days). The confirmed baseline and current eGFR values were 125 
subsequently allocated to the following eGFR strata: >90, >60-<90, >30-<60 and <30 ml/min/1.73m2. Where 126 
two consecutive eGFR values (<15% of all values) did not fall within the same eGFR strata, the mean of two 127 
eGFR values carried forward was used to assign an eGFR category. 128 
Individuals with a prior CVD event were included, but only the first CVD event experienced during 129 
prospective follow-up after baseline was included as an event. Individuals could however experience two or 130 
more different types of CVD event on the same date. 131 
Incidence rates were calculated per 1000 person years of follow-up (PYFU). Kaplan-Meier estimation was 132 
used to investigate time to CVD, stratified according to confirmed baseline eGFR levels (eGFR>90, <90->60, 133 
<60->30, <30 ml/min/1.73m2).  134 
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Poisson regression models stratified according to the confirmed current eGFR level were used to model the 135 
CVD incidence rate ratios, overall and stratified by individual CVD events. Potential confounders included in 136 
multivariate models were age (per 10 years older), gender, ethnicity, D:A:D enrolment cohort, nadir CD4 137 
count, mode of HIV acquisition and family history of CVD.  All  remaining variables were adjusted for as 138 
time-updated, including HBV/HCV co-infection, HIV-RNA (per log10), CD4 count, prior AIDS, hypertension 139 
(>150/>100 or receipt of antihypertensive treatment), diabetes (confirmed diagnosis of DM or receipt of 140 
anti-diabetic treatment), confirmed eGFR strata, smoking status (current, previous, never), dyslipidemia 141 
(total cholesterol >6.2 mmol/l, high-density lipoprotein cholesterol <0.9 mmol/l, triglyceride >2.3 mmol/l, 142 
or receipt of lipid-lowering treatment) and prior CVD (confirmed diagnosis). Antiretroviral drug use was 143 
fitted as time-updated cumulative use (per five years; zidovudine, didanosine, zalcitabine, stavudine, 144 
lamivudine, emtricitabine, tenofovir disoproxil fumerate, abacavir, efavirenz, nevirapine, indinavir, 145 
saquinavir, ritonavir, nelfinavir, (fos)ampreavir, atazanavir and darunavir) and current use (currently on and 146 
use with last six months; zidovudine, didanosine, zalcitabine, stavudine, lamivudine, emtricitabine, 147 
tenofovir disoproxil fumerate and abacavir).  148 
A number of sensitivity analyses were performed to test the robustness of the results. One analysis 149 
investigated death as a potential competing risk of CVD. Another analysis excluded all those with a prior 150 
CVD event. Other analyses adjusted for the D:A:D CKD risk-score [29] and the predicted CVD risk based on 151 
the Framingham CVD prediction model [30] to estimate how much of the CVD risk is explained through 152 
common renal and CVD risk factors. The D:A:D CKD risk score is a nine-variable prediction score estimating 153 
the five year risk of developing CKD in HIV-positive individuals. Individuals in the low CKD risk group (score 154 
<0) have a 1:393 (0.3%) five year CKD risk, rising to 1:47 (2.1%) in the medium (score 0-4) and 1:6 (16.7%) 155 
high risk group (score >5) [29].  A final analysis investigated the association between current nadir eGFR 156 
and the percentage of follow-up time spent with eGFR<60 ml/min/1.73m2 and CVD respectively. 157 
 158 
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Results 159 
Study population                                                                                                                                                                160 
35,357 persons with follow-up after 2004 and at least two eGFR measurement were included in analysis, 161 
Supplementary Figure 1. Included individuals were predominantly Caucasian (48.1%) males (73.9%) with a 162 
median age of 41 (interquartile range, IQR, 35-48) years, Table 1. While 41.6% were smokers, 4.0% had 163 
diabetes, 8.9% had hypertension and 0.7% had experienced a prior CVD event.  At baseline the median 164 
estimated five year risk of CKD was low overall (-1 (IQR -3 to4) corresponding to 0.3%) and medium (4 (IQR -165 
1to 9) corresponding to 2.1%) in those developing a CVD event, Table 1. 558 persons were excluded from 166 
analysis due to missing CD4 counts or viral load at baseline, or because of insufficient follow-up. Excluded 167 
persons were more likely to be young, of Caucasian origin, cART-naïve, HCV-positive, have no family history 168 
of CVD and have experienced a prior AIDS event.  169 
Age and eGFR level                                                                                                                                                            170 
Among individuals younger than 40 years 87.0% (n=13,660) had a normal (confirmed eGFR>90 171 
ml/min/1.73m2) baseline eGFR, and only 0.04% (n=7) had advanced renal impairment (confirmed baseline 172 
eGFR<30 ml/min/1.73m2). In contrast, among individuals older than 60 years, only 15.8% (n=321) had 173 
confirmed baseline eGFR>90ml/min/1.73m2 and 0.8% (n=17) confirmed baseline eGFR<30 ml/min/1.73m2. 174 
CVD events                                                                                                                                                                               175 
Over a median follow-up time of 8.0 years (IQR, 5.4-8.9, total PYFU 258,480) 1,357 persons developed 176 
1,646 CVD events (incidence rate 5.2 per 1000 PYFU [95% confidence interval, CI, 5.0-5.5]). The CVD events 177 
included 586 myocardial infarctions (11.1% fatal), 430 strokes (8.6% fatal), 510 coronary angioplasties (1.6% 178 
fatal), 96 coronary bypasses (2.1% fatal), 19 carotid endarterectomies (0% fatal) and 5 sudden cardiac 179 
deaths respectively. A total of 284 persons (21.0%) experienced more than one CVD event on the same 180 
date, most commonly a myocardial infarction and coronary angioplasty (n=259).  181 
 182 
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Median eGFR levels and incident CVD                                                                                                                                 183 
The median eGFR measured in individuals prior to their CVD event was significantly lower (85 (IQR 69-102) 184 
ml/min/1.73m2) than the median eGFR measured during follow-up in individuals not experiencing a CVD 185 
event (94 (IQR 79-110) ml/min/1.73m2, p<0.0001). Likewise, a greater proportion of individuals 186 
experiencing a CVD event had some level of confirmed reduced eGFR level, compared to individuals not 187 
experiencing an event, Figure 1. When comparing the individual types of CVD events, those experiencing a 188 
coronary bypass event had significantly lower confirmed eGFR levels compared to all other CVD event types 189 
(p=0.018). When excluding the coronary bypass events there was no statistically significant differences in 190 
confirmed eGFR levels prior to a CVD event (p=0.068). Likewise, when comparing those with an invasive 191 
cardiovascular procedures (coronary angioplasty, carotid endarterectomy or coronary bypass) to those with 192 
a myocardial infarction and/or stroke there was no statistical significant difference (p=0.55), Figure 1.   193 
Confirmed baseline eGFR levels and incident CVD                                                                                                                       194 
We observed a clear inverse relationship between confirmed eGFR levels at baseline and incident CVD with 195 
1.8% [95% CI 1.6-2.0%] estimated to have progressed to CVD at five years among those with confirmed 196 
baseline eGFR>90 ml/min/1.73m2, increasing to 4.1% (95% CI 3.5-4.6) for eGFR 60-90 ml/min/1.73m2, 197 
10.8% (95% CI 8.7-12.9) for baseline eGFR 30-60 ml/min/1.73m2 and 21.1% [95% CI 6.6-35.6%] among 198 
those with confirmed baseline eGFR<30 ml/min/1.73m2, Figure 2.   199 
Amongst individuals with moderately impaired baseline eGFR (confirmed eGFR<60 ml/min/1.73m2) who 200 
developed a CVD event, we did not observe a statistically significant differences (p=0.63) in time to 201 
different CVD events with a median time to CVD event of 45 months (IQR 21-76). 202 
Confirmed current eGFR level and incident CKD                                                                                                               203 
There was a strong and inverse linear relationship between confirmed current eGFR and CVD in univariate 204 
analysis; incidence rate ratios (IRRs) increasing from 1.00 at eGFR>90 ml/min/1.73m2   to 14.09 [95%CI 9.58-205 
20.74] at eGFR<30 ml/min/1.73m2, Figure 3. Adjusting for increasing age explained most of the relationship 206 
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between eGFR and CVD at eGFR levels >30 ml/min/1.73m2, although all eGFRs below 80 ml/min/1.73m2 207 
were associated with an increased incidence of CVD of approximately 30-40%.  At a confirmed current 208 
eGFR<30 ml/min/1.73m2 a significantly increased incidence of CVD remained independent of age (IRR 4.21 209 
[95%CI 2.81-6.30]), Figure 3. Further adjustment for other potential confounders including individual 210 
antiretroviral drugs had relatively limited impact on the overall association (IRR 3.08 [95%CI 2.04-4.65] at 211 
confirmed eGFR<30 ml/min/1.73m2 compared to confirmed eGFR>90 ml/min/1.73m2, Figure 3. The 212 
exclusion of the 240 individuals with a CVD event prior to baseline led to entirely consistent results (data 213 
not shown). 214 
In a bivariate analysis, adjusting for the Framingham score (as a continuous variable) explained some of the 215 
association between confirmed current eGFR and CVD, but not to the same extent as age alone (data not 216 
shown). In another analysis adjusting for the estimated five-year D:A:D CKD risk score individuals with a 217 
medium CKD risk (score 0-4) had a 2.56-fold increased incidence of CVD (IRR 2.56 [95%CI 2.22 – 2.95]) and 218 
individuals with a high CKD risk (score >5) had almost a five-fold increased incidence of CVD (IRR 4.98 [95% 219 
CI 4.37 – 5.68]) compared to persons with a low estimated CKD risk (score <0). After adjusting for other 220 
potential confounders (as shown in Figure 4) not included in the D:A:D CKD risk score (with the exception of 221 
age), those with a medium or high CKD risk score continued to have a significantly higher risk of CVD (IRR 222 
1.29 [95%CI 1.10-1.50] and 1.43 [95%CI 1.19-1.71] respectively). 223 
There was no strong evidence suggesting that the observed association between confirmed current eGFR 224 
levels and CVD differed amongst the individual types of CVD events. When restricting the analysis to fatal 225 
CVD events only, all observed associations were further strengthened (data not shown). Our findings were 226 
furthermore consistent in different age groups (test for interaction, p=0.88), and after accounting for death 227 
as a possible competing risk for CVD (data not shown). The association between CVD and confirmed eGFR 228 
seen in the primary analyses was largely unchanged by fitting renal function as current nadir eGFR and as 229 
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the percentage of follow-up spent with moderately impaired eGFR (eGFR<60 ml/min/1.73m2) (data not 230 
shown).  231 
Confirmed current eGFR levels and number of CVD events                                                                                                          232 
Individuals with higher confirmed current eGFR levels experienced two or more CVD events (at the same 233 
date) more frequently than those with lower eGFR levels (24.7% at eGFR>90 ml/min/1.73m2 vs.4.2% at 234 
eGFR<30 ml/min/1.73m2, p=0.0034), most commonly a myocardial infarction and coronary angioplasty. 235 
Furthermore, the proportion of individuals experiencing a fatal CVD event (death within 28 days following 236 
the event) was strongly related to the confirmed current eGFR level, increasing from 4.4% in individuals 237 
with a confirmed current eGFR>90 ml/min/1.73m2 to 25.0% in individuals with a confirmed current 238 
eGFR<30 ml/min/1.73m2 (p<0.0001).  239 
Discussion 240 
In this large heterogeneous cohort of HIV-positive individuals we found a strong association between 241 
centrally adjudicated CVD events and advanced levels of renal impairment (confirmed eGFR<30 242 
ml/min/1.73m2).  243 
Almost 60% of all individuals experiencing a CVD event had eGFR<90 ml/min/1.73m2, based on the latest 244 
median eGFR before the event, compared to less than 40% of those without an event. We further showed 245 
that development of a CVD event was considerately faster among those with a severely impaired eGFR at 246 
baseline. Among HIV-positive individuals with confirmed baseline eGFR<30 ml/min/1.73m2 over 20% were 247 
estimated to have developed CVD after five years.  248 
In previous studies from D:A:D we have investigated the inverse relation between CVD events and eGFR, 249 
focusing on CVD as a risk factor of various levels of chronic renal impairment [28, 29, 31]. Interestingly, 250 
these previous data also supported a strong association between CVD and renal function which significantly 251 
diminished after accounting for other risk factors suggesting an underlying biological mechanism at least 252 
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partly mediated by other factors. We have also previously showed an association between the use of 253 
certain antiretroviral drugs and CVD and renal impairment [28, 30, 32]. The results of this analysis are 254 
entirely consistent with these prior findings, and adjustment for the use of individual antiretroviral drugs 255 
did not have any major impact on the association between impaired eGFR and CVD. Data from this analysis 256 
points towards increasing age as the main underlying driver of the inverse relationship between  eGFR and 257 
CVD, in particular at mild to moderately impaired eGFR levels [14].  At more advanced levels of renal 258 
impairment (eGFR<30 ml/min/1.73m2) there are additional pathways between renal impairment and CVD, 259 
not immediately related to any of the known common risk factors on the shared causal pathway such as 260 
diabetes, hypertension and immunosuppression. Regardless of the underlying pathology the high rates of 261 
CVD observed in older individuals with mild to moderate renal impairment highlight the need for 262 
intensified monitoring and search for effective prophylactic measures for impaired renal function and CVD 263 
in the ageing HIV-population.  264 
In other studies of HIV-positive individuals, a smaller cross-sectional analysis in the FRAM study did not 265 
confirm an association between carotid intima-medial thickness and eGFR after accounting for older age, 266 
gender and ethnicity [13]. Likewise, a British study did not find an association between eGFR as a 267 
continuous variable and coronary heart disease, although those with eGFR<75 mL/min already had more 268 
than a 4-fold increased incidence [9]. In a recent EuroSIDA study both the follow-up time with a low eGFR 269 
and eGFR<30 ml/min/1.73m2 were predictive of non-AIDS events including CVD, but power was limited 270 
[12]. An older large cohort study among HIV-positive US veterans showed an almost 6-fold higher 271 
association between eGFR<30 ml/min, albuminuria and CVD, although this study also included peripheral 272 
artery disease and heart failure [10].  273 
Our findings do not suggest that the association between declining renal function and CVD is stronger, or 274 
starts at higher eGFR levels in HIV-positive persons than in the general population, as was hypothesised 275 
based on the higher occurrence of common renal and CVD risk factors and increased immune activation [1, 276 
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4, 33, 34]. There is, however, ongoing ambiguity, in the general population, regarding the strength of the 277 
association between impaired renal function and CVD.  Some studies report only on an association with 278 
CVD at advanced levels of renal impairment (eGFR<30 ml/min/1.73m2) while others report of associations 279 
already at higher eGFR levels [1, 4, 5, 9, 10, 14, 33, 34]. However, the definitions of CVD differ considerately 280 
in these studies ranging from subclinical imaging-verified diagnoses of atherosclerosis to various clinical 281 
events ascertained with different levels of certainty. The differences in the incidence of common risk 282 
factors and of CVD and renal impairment may also partly explain the conflicting results. Importantly, the 283 
D:A:D study focuses on ‘hard’ clinical CVD events exclusively and information on non-fatal heart failure or 284 
milder forms of ischemic CVD such as angina pectoris is not collected. This methodology may explain why 285 
more severe levels of renal impairment are necessary to establish an association with CVD. Interestingly, 286 
none of the widely accepted CVD risk prediction models currently include renal impairment in the 287 
estimates [30, 32], but  the proportion of individuals with advanced renal impairment may  be too limited 288 
to date. 289 
We also found that fatal outcomes of a CVD event were more common at lower compared to higher eGFR 290 
levels, which may be related to a more severe clinical event or to the fact that those with advanced levels 291 
of renal impairment provide a more fragile phenotype with less ability to cope with CVD complications. 292 
Likewise, fewer multiple CVD events occurred on the same date among those with lower eGFR levels. This 293 
finding may be related to the increased fatality rate at lower eGFR levelsor that those with lower eGFR 294 
levels are less likely to undergo invasive cardiovascular procedures as secondary prophylaxis, due to 295 
concerns about radiocontrast induced nephrotoxicity. Interestingly, there was no evidence of a relation 296 
between the eGFR level and type of CVD outcome i.e. a myocardial infarction did not seem to occur at 297 
different eGFR levels to other CVD events, with the exception of coronary bypass. Coronary bypass was 298 
more commonly carried out at lower eGFR levels, compared to the other CVD events, which may suggest 299 
more advanced atherosclerosis with multiple vessel disease in this population.  300 
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The potential limitations of the analysis should be acknowledged. We may have underestimated the 301 
proportion of individuals with an impaired eGFR level as those excluded from analysis were more likely to 302 
have common renal risk factors; hence the provided relation between eGFR and CVD is of a conservative 303 
nature. Proteinuria is a potential source of unmeasured confounding as it not collected systematically in 304 
the D:A:D study, and may further have moderating effects as it  is a strong independent risk factor for both 305 
CVD and CKD [35].Furthermore, renal impairment may have developed secondary to a CVD event as part of 306 
a cardiorenal syndrome, with potentials of reverse causality. However, in this analysis eGFR impairment 307 
proceeded all prospectively investigated CVD events [36]. Finally, non-ischemic events such as cardiac 308 
arrhythmias and ventricular hypertrophy were not directly included in the CVD definition, but may have 309 
contributed more indirectly via stroke and sudden cardiac death events.  310 
Conclusion 311 
In a large, contemporary cohort of HIV-positive individuals we observed a strong relationship between 312 
confirmed impaired renal function and incident CVD. More than one in five of those with advanced levels of 313 
renal impairment were estimated to have developed CVD by five years, with an increasing 28-day CVD 314 
fatality rate as eGFR declined. Our findings highlight the need for an intensified monitoring for emerging 315 
CVD, in particular in older individuals with continuously low eGFR levels. Our findings also call for an 316 
increased focus on applying different renal and cardiovascular preventive measures in HIV-positive 317 
individuals. 318 
 319 
 320 
 321 
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Table 1, Baseline Characteristics 502 
                                    All       Persons developing CVD 
    N % N % 
All   35,357 100 1,357 3.8 
Gender Male 26,124 73.9 1,181 87.3 
Ethnicity Caucasian 17,016 48.1 697 51.4 
 Black 2,450 6.9 40 3.0 
 Other 716 2.0 12 0.9 
 Unknown 15,175 42.9 608 44.8 
Mode of HIV acquisition MSM 16,234 45.9 728 53.7 
 IDU 4,529 12.8 154 11.4 
 Heterosexual 12,436 35.2 386 28.4 
 Other 2,158 6.1 89 6.6 
HBV1 Positive 1,597 4.5 46 3.4 
 Negative 31,169 88.2 1,213 89.4 
 Unknown 2,591 7.3 98 7.2 
HCV2 Positive 6,479 18.3 236 17.4 
 Negative 25,535 72.2 973 71.7 
 Unknown 3,343 9.5 148 10.9 
cART On 26,425 74.7 1,197 88.2 
Prior AIDS event Yes 8,768 24.8 462 34.1 
VL<400 (copies/mL) Yes 20,828 58.9 956 70.4 
Smoking Current 14,715 41.6 688 50.7 
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Baseline defined as 01/02/2004                                                                                                                                                         503 
1. HBV defined as positive: HBV surface antigen, HBV e antigen, or HBV DNA positive                                                                                                                                       504 
2. HCV defined as anti-HCV positive and HCV-RNA positive/unknown                                                                                           505 
3. Prior CVD, as diagnosed on a D:A:D CVD event form                                                                                                                     506 
4. Hypertension defined as blood pressure >150/>100 or antihypertensive treatment                                                                                  507 
5. Diabetes as diagnosis on a D:A:D event form or by use of anti-diabetic treatment                                                                                   508 
6. eGFR calculated using Cockcroft-Gault                                                                                                                                                              509 
7. Score <0: low 5-year CKD risk (0.3%), Score 0-4: medium 5-year CKD risk (2.1%) and Score >5: high 5-year CKD risk 510 
(16.7%) 511 
BMI (Kg/m2) >30 1,830 5.2 78 5.7 
CVD Family History Yes 2,712 7.7 179 13.2 
Prior CVD3  Yes 240 0.7 72 5.3 
Hypertension4  Yes 3,133 8.9 264 19.5 
Diabetes5  Yes 1,425 4.0 163 12.0 
eGFR (ml/min/1.73m2)6 >90 24,937 70.5 656 48.3 
 >60-<=90 9,378 26.5 559 41.2 
 
>30-<=60 999 2.8 13.5 10.0 
 
<=30 43 0.1 7 0.5 
Fragminham risk  score  
                                           Low (0-5%)              24,111               68.2            275                  18.9          
                                           Moderate (5-10%)    5,821               16.5           290                   21.4 
                                           High (>10%)               5,425               15.3            810                  59.7 
D:A:D CKD risk7               Risk score                     -1                  -3 to 4              4                 -1 to 9 
(median, IQR)               
Age (median, IQR) Years 41      35-48 50 44-59 
CD4 (median, IQR) cells/mm3 44    290-625 441  289-640 
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Figure 1, Confirmed Current eGFR Level Prior to CVD Event 512 
Confirmed current eGFR level for those with a CVD event is the last measured median eGFR level prior the event. For 513 
those without a CVD event confirmed current eGFR level is the last measured median eGFR level during follow-up. 514 
 515 
Figure 2, Kaplan-Meier Progression to CVD By Confirmed Baseline eGFR Level 516 
 517 
Figure 3, CVD Incidence Rate Ratios by Confirmed Current eGFR Level 518 
Multivariate analysis adjusted for age, gender, ethnicity, D:A:D enrolment cohort, nadir CD4 count, HIV mode of 519 
acquisition and family history of CVD at baseline. Time-updated variables include HBV/HCV co-infection, HIV-RNA, CD4 520 
count, prior AIDS, hypertension, diabetes, confirmed eGFR strata, smoking status, dyslipidemia, prior CVD, exposure 521 
to antiretroviral drugs fitted as cumulative use (to zidovudine, didanosine, zalcitabine, stavudine, lamivudine, 522 
emtricitabine, tenofovir disoproxil fumerate, abacavir, efavirenz, nevirapine, indinavir, saquinavir, ritonavir, nelfinavir, 523 
(fos)ampreavir, atazanavir and darunavir) and current use (zidovudine, didanosine, zalcitabine, lamivudine, stavudine, 524 
emtricitabine, tenofovir disoproxil fumerate and abacavir).  525 
 526 
                                             Supplementary Document 1, Figure 1, Inclusion of Individuals in Analysis 527 
 528 
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